WO2021248276A1 - Anti-sar-cov-2 antibody or antigen-binding fragment thereof and use thereof - Google Patents

Abstract

The present invention relates to an anti-SAR-COV-2 antibody or an antigen-binding fragment thereof and the use thereof. The antibody and the antigen-binding fragment thereof have heavy chain complementarity determining regions as shown in SEQ ID Nos: 1-3 and light chain complementarity determining regions as shown in SEQ ID Nos: 4-6, or have heavy chain complementarity determining regions as shown in SEQ ID Nos: 7-9 and light chain complementarity determining regions as shown in SEQ ID Nos: 10-12, or have heavy chain complementarity determining regions as shown in SEQ ID Nos: 13-15 and light chain complementarity determining regions as shown in SEQ ID Nos: 16-18, or have heavy chain complementarity determining regions as shown in SEQ ID Nos: 19-21 and light chain complementarity determining regions as shown in SEQ ID Nos: 22-24. The antibody is a humanized antibody and is low in side effects and high in affinity and specificity.

Description

Anti-SAR-COV-2 antibody or its antigen binding fragment and application thereof Technical field

The present invention belongs to the field of immunological antibodies, and specifically relates to an anti-SAR-COV-2 (COVID-19) fully human monoclonal antibody and its preparation method and application.

Background technique

Among the top ten best-selling drugs in the world in 2018, 8 are fully human or humanized monoclonal antibody drugs. Ranked first is AbbVie's anti-TNFa monoclonal antibody Humira for treating arthritis. This is a fully human monoclonal antibody that has been the king of drugs with sales of more than 10 billion for 6 consecutive years. From the launch of the first monoclonal antibody drug in 1986, monoclonal antibody drugs have experienced mouse-derived monoclonal antibody drugs (such as Orthoclone OKT3), chimeric monoclonal antibody drugs (Rituximab), humanized monoclonal antibody drugs (Herceptin) and whole-human Source monoclonal antibody (Humira) and other stages. Due to the emergence of anti-mouse antibody response (HAMA) in the human body, mouse-derived monoclonal antibody drugs and chimeric monoclonal antibody drugs have been gradually eliminated. The monoclonal antibody drugs currently occupying the market are all humanized monoclonal antibody drugs. Compared with the international advanced human antibody production technology, Shenzhen and even the whole of China have a big gap, which is mainly manifested in the weak innovation ability in the field of human antibody drugs, and there are few independent research and development varieties. There is no original humanized monoclonal antibody. According to reports of antibody drugs on the market, the huge antibody drug market is occupied by foreign pharmaceutical companies. If my country wants to change its backward situation and compete for the antibody drug market at home and abroad with huge consumption potential, it is urgent to conquer the fully human monoclonal antibody technology.

Human-derived monoclonal antibodies have high specificity and significant curative effects in the treatment of inflammation, cancer, influenza, especially coronavirus infections. COVID-19 is an acute respiratory infectious disease caused by a SAR-COV-2 coronavirus. It caused a global pandemic in 2020 and seriously threatened human life and property. As of May 22, 2020, a total of 5,113,375 people have been infected with SAR-COV-2 and 330,052 people have died. There is still a lack of effective drugs and vaccines. When the new coronavirus invades cells, it needs to rely on the specific molecular spike protein (Spike, S protein) expressed by the virus to bind to receptors on human cells in order to infect the cells and further expand. The human antibodies that neutralize the virus are some specific antibodies produced by human B lymphocytes, which can bind to the antigen on the surface of the virus, thereby preventing the virus from adhering to the target cell receptor, preventing the virus from invading the cell, and effectively preventing SAR-COV-2 influenza. However, there is still no effective human-specific antibody available.

Summary of the invention

To solve the above problems, the present invention provides an anti-SAR-COV-2 antibody or antigen-binding fragment thereof, which specifically neutralizes SAR-COV-2.

One aspect of the present invention provides an isolated anti-SAR-COV-2 antibody or antigen-binding fragment thereof, said antibody or antigen-binding fragment thereof specifically binds to SAR-COV-2 surface S protein; it has any of the following groups The three heavy chain complementarity determining regions (HCDR) and three light chain complementarity determining regions (LCDR):

1) 9g8

HCDR1: GGSITTSSDY SEQ ID No: 1;

HCDR2: IYYSGRT SEQ ID No: 2;

HCDR3: ARRLTYYYDSSGYANWYFDL SEQ ID No: 3;

LCDR1: QRFSTF SEQ ID No: 4;

LCDR: 2: AAS SEQ ID No: 5;

LCDR3: QQSYSIPYS SEQ ID No: 6; or

2) 6J19

HCDR1: GFTFSSYS SEQ ID No: 7;

HCDR2: ISSSGTFI SEQ ID No: 8;

HCDR3: ARERFVGVLDI SEQ ID No: 9;

LCDR1: SSNIGRST SEQ ID No: 10;

LCDR: 2: SSY SEQ ID No: 11;

LCDR3: AAWDDSLNGPV SEQ ID No: 12; or

3) 7N13

HCDR1: GFTFSSYS SEQ ID No: 13;

HCDR2: ISSSSSTM SEQ ID No: 14;

HCDR3: ARGVGATGELFDY SEQ ID No: 15;

LCDR1: QGIGNE SEQ ID No: 16;

LCDR: 2: AAS SEQ ID No: 17;

LCDR3: LQDYNYPRT SEQ ID No: 18; or

4) 8L19

HCDR1: GFTFSNYS SEQ ID No: 19;

HCDR2: ISTTGTYT SEQ ID No: 20;

HCDR3: ARPYYYGSGSPDY SEQ ID No: 21;

LCDR1: QSISTF SEQ ID No: 22;

LCDR: 2: AAS SEQ ID No: 23;

LCDR3: HQTYSKPWT SEQ ID No: 24; or

5) 6M9

HCDR1: GFTFRNYD SEQ ID No: 25;

HCDR2: ISGSGIDT SEQ ID No: 26;

HCDR3: VRGLAGAFDY SEQ ID No: 27;

LCDR1: QSVTSGY SEQ ID No: 28;

LCDR: 2: GTS SEQ ID No: 29;

LCDR3: QQHRSSPMYS SEQ ID No: 30.

Another aspect of the present invention provides an isolated anti-SAR-COV-2 antibody or antigen-binding fragment thereof, which has a heavy chain variable region and a light chain variable region as shown below;

1) 9g8

Heavy chain variable region:

Light chain variable region:

DIQMTQSPSSLSASVGDRVTITCRASQRFSTFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSIPYSFGQGTKLEIKR SEQ ID No: 32; or

2) 6J19

Heavy chain variable region:

Light chain variable region:

QSVLTQPPSASGTPGERVTISCSGSSSNIGRSTVSWYQQLPGTAPKLLMYSSYQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKLTVLG SEQ ID No: 34; or

3) 7N13

Heavy chain variable region:

Light chain variable region:

AIQMTQSPSSLSASVGDRVTITCRATQGIGNELGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPRTFGQGTKVEIKR SEQ ID No: 36; or

4) 8L19

Heavy chain variable region:

Light chain variable region:

DIQMTQSPSSLSASVGDRVTITCRASQSISTFLNWYQQKPGKAPNLLIYAASSLQRGVPSRFTGSGSGTDFTLTISSLQPEDFATYYCHQTYSKPWTFGRGTKVEIER SEQ ID No: 38; or

5) 6M9

Heavy chain variable region:

Light chain variable region:

In the technical solution of the present invention, the antibody or antigen-binding fragment thereof is a humanized antibody, more preferably a fully humanized antibody.

In the technical solution of the present invention, the antibody is a monoclonal antibody or a polyclonal antibody, preferably a monoclonal antibody.

In the technical scheme of the present invention, the antibody or antigen-binding fragment thereof specifically binds to the S protein on the surface of SAR-COV-2.

Another aspect of the present invention provides a nucleotide sequence that encodes the aforementioned antibody or antigen-binding fragment thereof.

Another aspect of the present invention provides a vector comprising the aforementioned nucleotide sequence.

Another aspect of the present invention provides a host cell comprising the aforementioned vector or vector group. Preferably, the host cell is prokaryotic or eukaryotic, more preferably selected from yeast cells, mammalian cells or suitable for preparing antibodies Or other cells of antigen-binding fragments thereof.

Another aspect of the present invention provides a kit comprising the aforementioned antibody or antigen-binding fragment thereof.

Another aspect of the present invention provides a detection reagent, which comprises the aforementioned antibody or antigen-binding fragment thereof.

Another aspect of the present invention provides the use of the above-mentioned antibody or antigen-binding fragment thereof as a detection reagent, and the reagent is used for the following purposes: enzyme-linked immunosorbent assay (ELISA), western blot (Western Blot), flow cytometry (FACS), immunohistochemistry (IHC) detection or immuno-PCR.

In the above immunological detection, the antibody or its antigen-binding fragment can be coupled alone or with a chemical bond, electrostatic adsorption or hydrophobic adsorption, and the linking conjugate includes horseradish peroxidase (HRP), alkaline phosphatase (AP), Biotin (Biotin), Fluorescein isothiocyanate (FITC), Cy3, Cy5, magnetic beads and agarose and other conjugates are connected.

In the technical scheme of the present invention, the detection reagent can be used for non-diagnostic or therapeutic purposes.

Another aspect of the present invention provides a pharmaceutical composition, the antibody or antigen-binding fragment thereof isolated as described above, and pharmaceutically acceptable excipients.

In the technical solution of the present invention, wherein the antibody or antigen-binding fragment thereof blocks or reduces the binding of the S protein of SAR-COV-2 to the cell surface receptor of the subject, and the cell surface receptor is preferably a cell blood vessel Tentensin converting enzyme-related carboxypeptidase (ACE2).

Another aspect of the present invention provides the use of an anti-SAR-COV-2 antibody or antigen-binding fragment thereof in the preparation of a medicament for preventing, treating or alleviating at least one symptom or indication of SAR-COV-2 infection.

In the technical scheme of the present invention, the drug is an oral or injection preparation.

Another aspect of the present invention provides a method for preventing, treating or alleviating at least one symptom or indication of SAR-COV-2 infection, the method comprising combining the antibody or antigen-binding fragment of any one of the foregoing or the foregoing drug The composition is administered to the subject.

In the technical scheme of the present invention, the at least one symptom or indication is selected from the group consisting of lung inflammation, alveolar injury, fever, cough, dyspnea, hypoxemia, acute respiratory distress syndrome, sepsis Symptomatic shock, coagulopathy, metabolic acidosis, nasal congestion, runny nose, sore throat, diarrhea, organ failure, septic shock and death.

In the technical solution of the present invention, wherein the pharmaceutical composition or the antibody or antigen-binding fragment thereof is administered in combination with a second therapeutic agent. Wherein the second therapeutic agent is selected from the following group: anti-inflammatory drugs (such as corticosteroids and non-steroidal anti-inflammatory drugs), antiviral drugs, different antibodies against the S protein of SAR-COV-2, and for SAR-COV -2 vaccines, antibiotics, dietary supplements such as antioxidants, and any other palliative therapy for the treatment of SAR-COV-2 infection, drugs to relieve the above symptoms or indications.

In the technical solution of the present invention, wherein the pharmaceutical composition or the antibody or antigen-binding fragment thereof is administered subcutaneously, intravenously, intracutaneously, intraperitoneally, orally, intramuscularly or intracranially.

Beneficial effect

(1) The anti-SAR-COV-2 antibody of the present invention can target to bind to the S protein of SAR-COV-2 virus, with high specificity, and can effectively block the surface S protein of SAR-COV-2 virus from the subject cells Surface receptor binding.

(2) Compared with mouse-derived antibodies, the genes of the fully human antibodies of the present invention are completely derived from human genes and have no components of other species. They do not have toxic and side effects such as anti-mouse and anti-antibodies in the human body, and have better biological characteristics. Capacitive, more suitable and more potential to become a macromolecular drug for the treatment of influenza virus.

(3) Compared with the method for preparing human monoclonal antibodies against SAR-COV-2 virus provided by the phage display technology provided in the prior art, the single B cell used in the present invention has simple operations to develop antibodies against SAR-COV-2 virus. It is fast, and the human antibody produced has the advantages of high affinity and specificity.

Description of the drawings

Figure 1 is a flow cytometric test result of NTH-3T3 expressing CD40L in Example 1.

Fig. 2 is a diagram showing the result of sorting memory B cells by flow cytometry in Example 1.

Figure 3 is a graph showing the results of the ELISA experiment in Example 1.

Figure 4 is a graph showing the results of agarose gel electrophoresis in Example 2.

detailed description

In order to have a clearer understanding of the technical features, purposes and beneficial effects of the application, the technical solutions of the application are described in detail below in conjunction with specific embodiments. It should be understood that these examples are only used to illustrate the application and not to limit the scope of the application. . In the examples, all the original reagent materials are commercially available, and the experimental methods without specific conditions are the conventional methods and conventional conditions well-known in the art, or according to the conditions recommended by the instrument manufacturer.

As used herein, the term "antibody" refers to a molecule comprising at least one antigen binding site that immunospecifically binds to a specific target antigen target. Therefore, the term "antibody" includes, but is not limited to, full-length antibodies and/or variants thereof, fragments thereof, peptide bodies and variants thereof, monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, consisting of at least two Multispecific antibodies (such as bispecific antibodies), human antibodies, humanized antibodies, and antibody mimics that mimic the structure and/or function of antibodies or designated fragments or parts thereof, including single-chain antibodies and Fragment. The binding of the antibody to the target can cause a variety of effects, such as but not limited to such binding in vitro, in situ and/or in vivo regulation, reduction, increase, antagonism, agonism, reduction, slowing, blocking, inhibition, elimination and/or Interference with at least one target activity or binding, or receptor activity or binding. Therefore, the antibodies of the present disclosure encompass antibody fragments capable of binding to biomolecules (such as antigens or receptors) or parts thereof, including but not limited to Fab, Fab' and F(ab')2, pFc', Fd, single domain antibodies (sdAb), variable fragment (Fv), single-chain variable fragment (scFv) or disulfide-linked Fv (sdFv); bifunctional antibody or bivalent bifunctional antibody; linear antibody; single-chain antibody molecule; by antibody Multispecific antibodies formed by fragments. Antibodies can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) or subclass.

As used herein, the term "monoclonal antibody" refers to an antibody derived from a group of antibodies of the same species, that is, except for the possibility of a small number of mutations that may occur naturally, each antibody constituting the population is the same. Monoclonal antibodies are highly specific and are directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations containing different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to its specificity, the advantage of monoclonal antibodies is that they can be synthesized without contaminating other antibodies. The modifier "monoclonal" should not be interpreted as requiring the production of antibodies by any specific method.

As used herein, the term HCDR has the same meaning as the heavy chain complementarity determining region, and LCDR has the same meaning as the light chain complementarity determining region.

As used herein, monoclonal antibodies include "chimeric" antibodies in which a portion of the heavy chain and/or light chain is the same or homologous to the corresponding sequence in an antibody derived from a specific species or belonging to a specific anti-class or subclass, and The rest of the chain is identical or homologous to the corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass, and fragments of these antibodies exhibit the desired biological activity.

As used herein, the term "SAR-COV-2" is also referred to as "new coronavirus", which refers to a newly-occurring virus that causes new coronavirus pneumonia (COVID-19).

As used herein, the S protein refers to the spike protein on the coronavirus. SARS-CoV-2 recognizes the ACE2 on the cell surface of the human body through the spike protein on the surface of the virus and infects host cells. By blocking the S protein on the surface of the coronavirus SARS-CoV-2, it can effectively inhibit the virus from adhering to the target cell receptor and prevent the virus from invading the cell.

The term "humanized antibody" as used herein includes antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human humanized antibody of the present invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or in vitro site-specific mutagenesis or by somatic mutation in vivo).

The term anti-"antigen-binding fragment" and the like as used herein includes any naturally-occurring, enzymatically obtainable, synthetic or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. As used herein, the term "antigen-binding fragment" of an antibody has one or more fragments that have the ability to bind to the S protein of SAR-COV-2.

In one aspect, the present invention provides an isolated anti-SAR-COV-2 antibody or antigen-binding fragment thereof, said antibody or antigen-binding fragment thereof specifically binds to SAR-COV-2 surface S protein; it has any of the following Set of three heavy chain complementarity determining regions (HCDR) and three light chain complementarity determining regions (LCDR):

1) 9g8

HCDR1: GGSITTSSDY SEQ ID No: 1;

HCDR2: IYYSGRT SEQ ID No: 2;

HCDR3: ARRLTYYYDSSGYANWYFDL SEQ ID No: 3;

LCDR1: QRFSTF SEQ ID No: 4;

LCDR: 2: AAS SEQ ID No: 5;

LCDR3: QQSYSIPYS SEQ ID No: 6; or

2) 6J19

HCDR1: GFTFSSYS SEQ ID No: 7;

HCDR2: ISSSGTFI SEQ ID No: 8;

HCDR3: ARERFVGVLDI SEQ ID No: 9;

LCDR1: SSNIGRST SEQ ID No: 10;

LCDR: 2: SSY SEQ ID No: 11;

LCDR3: AAWDDSLNGPV SEQ ID No: 12; or

3) 7N13

HCDR1: GFTFSSYS SEQ ID No: 13;

HCDR2: ISSSSSTM SEQ ID No: 14;

HCDR3: ARGVGATGELFDY SEQ ID No: 15;

LCDR1: QGIGNE SEQ ID No: 16;

LCDR: 2: AAS SEQ ID No: 17;

LCDR3: LQDYNYPRT SEQ ID No: 18; or

4) 8L19

HCDR1: GFTFSNYS SEQ ID No: 19;

HCDR2: ISTTGTYT SEQ ID No: 20;

HCDR3: ARPYYYGSGSPDY SEQ ID No: 21;

LCDR1: QSISTF SEQ ID No: 22;

LCDR: 2: AAS SEQ ID No: 23;

LCDR3: HQTYSKPWT SEQ ID No: 24; or

5) 6M9

HCDR1: GFTFRNYD SEQ ID No: 25;

HCDR2: ISGSGIDT SEQ ID No: 26;

HCDR3: VRGLAGAFDY SEQ ID No: 27;

LCDR1: QSVTSGY SEQ ID No: 28;

LCDR: 2: GTS SEQ ID No: 29;

LCDR3: QQHRSSPMYS SEQ ID No: 30.

Another aspect provides an isolated anti-SAR-COV-2 antibody or antigen-binding fragment thereof, which has a heavy chain variable region and a light chain variable region as shown below;

1) 9g8

Heavy chain variable region:

Light chain variable region:

DIQMTQSPSSLSASVGDRVTITCRASQRFSTFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSIPYSFGQGTKLEIKR SEQ ID No: 32; or

2) 6J19

Heavy chain variable region:

Light chain variable region:

QSVLTQPPSASGTPGERVTISCSGSSSNIGRSTVSWYQQLPGTAPKLLMYSSYQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKLTVLG SEQ ID No: 34; or

3) 7N13

Heavy chain variable region:

Light chain variable region:

AIQMTQSPSSLSASVGDRVTITCRATQGIGNELGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPRTFGQGTKVEIKR SEQ ID No: 36; or

4) 8L19

Heavy chain variable region:

Light chain variable region:

DIQMTQSPSSLSASVGDRVTITCRASQSISTFLNWYQQKPGKAPNLLIYAASSLQRGVPSRFTGSGSGTDFTLTISSLQPEDFATYYCHQTYSKPWTFGRGTKVEIER SEQ ID No: 38; or

5) 6M9

Heavy chain variable region:

Light chain variable region:

In some embodiments, the antibody is a humanized antibody, and in some specific embodiments, it is preferably a fully humanized antibody.

In some embodiments, the antibody is a monoclonal antibody or a polyclonal antibody, preferably a monoclonal antibody.

In some embodiments, the antibody or antigen-binding fragment thereof specifically binds to the S protein on the surface of SAR-COV-2.

In some embodiments, the amino acid sequence of the variable region of the heavy chain or the variable region of the light chain of the antibody may be an amino acid sequence with equivalent functions formed by substitution, deletion or addition of one or several amino acids.

In some embodiments, it is verified by ELISA experiments that the anti-SAR-COV-2 antibody or antigen-binding fragment of the present invention can target to bind to the S protein of the SAR-COV-2 virus. The antibodies described in this application are fully human monoclonal antibodies. Compared with murine antibodies, the genes of fully human antibodies are completely derived from human genes, without components from other species, and no anti-mouse anti-antibodies, etc. occur in the human body. Toxic and side effects, with better biocompatibility, more suitable and more potential to become a macromolecular drug for the treatment of influenza virus.

On the other hand, this application provides a gene encoding the anti-SAR-COV-2 fully human monoclonal antibody described in this application. In some embodiments, the gene includes a nucleotide sequence encoding the amino acid shown above.

In some specific embodiments, the nucleotide sequence is as follows (the following sequence is only exemplary, and those skilled in the art can design other nucleotide sequences that can be translated into the desired amino acid sequence according to the specific amino acid sequence):

1) 9g8

The nucleotide sequence encoding the variable region of the heavy chain is:

The nucleotide sequence encoding the variable region of the light chain is:

2) 6J19

The sequence encoding the variable region of the heavy chain is:

The nucleotide sequence encoding the variable region of the light chain is:

3) 7N13

The nucleotide sequence encoding the variable region of the heavy chain is:

The nucleotide sequence encoding the variable region of the light chain is:

4) 8L19

The nucleotide sequence encoding the variable region of the heavy chain is:

The nucleotide sequence encoding the variable region of the light chain is:

5) 6M9

The nucleotide sequence encoding the variable region of the heavy chain is:

The nucleotide sequence encoding the variable region of the light chain is:

In another aspect, the present invention provides a vector containing the nucleotide sequence as described above.

In another aspect, the present application provides a cell containing the nucleotide sequence as described above or the vector as described above.

In another aspect, the present application provides a method for producing the anti-SAR-COV-2 fully human monoclonal antibody or a biologically active fragment derived from the monoclonal antibody capable of specifically binding to SAR-COV-2. The method Including culturing the above-mentioned gene or genetically engineered cell containing the above-mentioned vector containing the heavy and light chain encoding the anti-SAR-COV-2 fully human monoclonal antibody or directly culturing the above-mentioned cells, collecting and purifying to obtain the anti-SAR-COV-2 fully human Source monoclonal antibodies.

In the prior art, there is a method for preparing human monoclonal antibodies against the SAR-COV-2 virus by using phage display technology. Although this method has the advantages of low production cost and no cumbersome work such as immunization and cell fusion, its shortcomings are also relatively low. Obviously, antibodies obtained from non-immune antibody libraries often have insufficient affinity, are limited by the conversion rate of foreign genes, and the capacity of the antibody library is not sufficient to cover the diversity of animal antibodies. Therefore, the present invention provides an antibody screening method, which isolates B cells that secrete functional antibodies from the blood of patients, then extracts RNA and synthesizes cDNA, clones the genes that secrete the antibodies of interest, and finally recombines and expresses fully human monoclonal antibody. The technology is simple and quick to operate, and the human antibodies produced have high affinity and specificity. In addition, the improved technology for isolating the monoclonal antibodies described in this application that has the function of neutralizing viruses or killing tumors from memory B cells can be further used. It greatly reduces the tedious operation and cost.

On the other hand, this application provides a pharmaceutical composition comprising the anti-SAR-COV-2 fully human monoclonal antibody described in this application or a monoclonal antibody derived from the monoclonal antibody capable of specifically binding to SAR-COV-2 Biologically active fragments.

On the other hand, this application provides the anti-SAR-COV-2 fully human monoclonal antibody or the biologically active fragment derived from the monoclonal antibody capable of specifically binding to SAR-COV-2 or the pharmaceutical composition Application in the preparation of medicines for treating diseases caused by SAR-COV-2 virus.

On the other hand, the present application provides a kit for detecting the level of SAR-COV-2 virus, which contains the anti-SAR-COV-2 fully human monoclonal antibody described in this application or a specific monoclonal antibody derived from the monoclonal antibody. Sexually binds biologically active fragments of SAR-COV-2; in some embodiments, the kit further contains a second antibody and an enzyme or fluorescent or radiolabel for detection, and a buffer; the second antibody For example, it is an anti-antibody against the monoclonal antibody described in this application.

Example 1

(1) Construction of NTH-3T3 cell line (3T3-CD40L) stably expressing CD40L

Use lentivirus to establish 3T3-CD40L feeder cells. The lentiviral expression vector pLVX-CD40L was constructed and transfected into 293T cells. The viral supernatant was collected on the fourth day of transfection. Activated NIH-3T3 cells, cultured for 3 generations, infected with lentivirus, continued to culture and passage 3 times. Use flow cytometry to sort cells with FITC fluorescence intensity near MFI, re-add them to the culture flask, _{culture and test in a 37°C, 5% CO 2} incubator, the test results are shown in Figure 1, which is to express CD40L 3T3 cells and 3T3 cells transfected with empty vector pLVX (with ZxGreen) were stained with anti-CD40L with APC, and then analyzed by flow cytometry. It was found that all 3T3-CD40L feeder cells express CD40L. When the cells grow to 80%-90%, digest and collect the cells at a concentration of 1×10 ⁷ cells per milliliter. Place it in a radiometer for 5000rads radiation, and resuspend the cells in the cryopreservation solution at a concentration of 3.5×10 ⁷ cells per milliliter. Aliquot 1ml into cryovials and freeze in liquid nitrogen (can be stored for 2 years).

(2) Sorting and activation of memory B cells

The peripheral blood mononuclear cells (PBMC) of convalescent patients who had been infected with SAR-COV-2 virus were separated and frozen with lymphatic separation fluid, 10-50×10 ⁶ cells per tube, and frozen in a liquid nitrogen tank. Prepare PBMC flow dyeing solution, its components are shown in Table 1 below

Table 1 PBMC flow dyeing solution

antibody	Volume (μL)
CD19-PE-Cy7	0.5
IgM-PE	1.0
IgA-APC	2.5
IgD-FITC	2.5
PBS-1%(wt/vol)BSA	43.5

Thaw PBMC, add the above-mentioned PBMC flow cytometry staining solution and sort on a flow cytometer. The result is shown in Figure 2. ^{The memory B cells of CD19 +} IgM ^– IgA ^– IgD ^– are sorted, and the cell purity needs to be above 90% If it is less than 90%, repeat the sorting process. Prepare a mixed medium for activating B cells, as shown in Table 2 below:

Table 2

Component	volume
Complete IMDM medium	336mL
IL-2(10,000U mL -1 )	3.5mL
IL-21(100μg mL -1 )	175μL
3T3-CD40L obtained in step (1)	10mL

The memory B cells were added to the mixed medium, mixed and then diluted in a 384-well plate with 1 cell per well with a volume of 50 μl, and placed in a 37°C, 5% CO ₂ incubator for static culture. After 13 days, the supernatant was taken to obtain human monoclonal antibodies 9g8, 6J19, 7N13, 8L19 and 6M9.

(3) Human monoclonal antibody binding to the surface antigen S protein of SAR-COV-2 virus

The surface antigen S protein of SAR-COV-2 virus was purchased from Yiqiao Shenzhou Company. It is immunogenic. Anti-S protein antibodies can be used to detect and treat SAR-COV-2 coronavirus. ELISA experiments were performed on the five human monoclonal antibodies 6J19, 7N13, 8L19 and 6M9 obtained above, specifically:

(1) Coat 100ng/100μl of HA protein of SAR-COV-2 virus in a 96-well microtiter plate, 100μl per well;

(2) Place in a 4℃ refrigerator overnight;

(3) Wash three times with PBST solution, add 200μl of 5% skimmed milk powder solution to each well, and incubate at 37°C for 1 hour;

(4) Wash three times with PBST solution, add 100μl of normal human serum (negative control) or supernatant that is not infected with virus, and repeat three times for each;

(5) After incubating at 37°C for 1 hour, wash with PBST solution three times;

(6) Dilute the anti-human IgG antibody (abcam) with HRP at 1:5000, add it to the enzyme-labeled plate, 100μl per well;

(7) After incubating at 37°C for 1 hour, wash with PBST solution three times;

(8) Add 100μl TMB substrate solution (Thermo Scientific) to each well, 37°C for 5 minutes;

(9) Add 100μl of stop solution 2M sulfuric acid to each well, and immediately detect the absorbance at 450nm wavelength in the microplate reader. The results are shown in Fig. 3, and ELISA experiments show that the human monoclonal antibodies 6J19, 7N13, 8L19 and 6M9 obtained in the present invention can all target and bind to the S protein of the SAR-COV-2 virus.

Example 2 Cloning of humanized monoclonal antibody gene

The B cells that can secrete antibodies that bind to the SAR-COV-2 virus obtained in Example 1 were lysed, and the lysate was taken to perform reverse transcription of RNA to obtain the PCR template cDNA of the human antibody gene. Design and synthesize primers for cloning antibody genes, use cDNA as template to clone antibody heavy and light chain genes, and send them to Jinweizhi Company for sequencing. specifically:

(1) Transfer the lysed B cell liquid to a 96-well plate (Eppendorf, 030133366).

(2) Reverse transcription system: 150ng random primer (invitrogen, 48190-011), 0.5μl 10mM dNTP (Invitrogen, 18427-088), 1μl 0.1M DTT (Invitrogen, 18080-044), 0.5%v/v Igepal CA -630 (Sigma, I3021-50ML), 4U RNAsin (Promega), 6U Prime RNAse Inhibitor (Eppendorf) and 50U

III reverse transcriptase (Invitrogen, 18080-044), supplement with DEPC water to 14μl/well.

(3) Reverse transcription reaction program: 42°C, 10min; 25°C, 10min; 50°C, 60min; 94°C, 5min.

(4) cDNA is stored at -20°C.

(5) Design and synthesis of primers:

Forward Primer 5′-3′ sequence (Forward Primer 5′-3′ sequence)

PCR primers for heavy chain variable region:

5′VH1 CTGCAACCGGTGTACATTCCCAGGTGCAGCTGGTGCAG (SEQ ID NO: 51)

5′VH1/5 CTGCAACCGGTGTACATTCCGAGGTGCAGCTGGTGCAG (SEQ ID NO: 52)

5′VH3 CTGCAACCGGTGTACATTCTGAGGTGCAGCTGGTGGAG (SEQ ID NO: 53)

5′VH3-23 CTGCAACCGGTGTACATTCTGAGGTGCAGCTGTTGGAG (SEQ ID NO: 54)

5′VH4 CTGCAACCGGTGTACATTCCCAGGTGCAGCTGCAGGAG (SEQ ID NO: 55)

5′VH 4-34 CTGCAACCGGTGTACATTCCCAGGTGCAGCTACAGCAGTG (SEQ ID NO: 56)

5′VH 1-18 CTGCAACCGGTGTACATTCCCAGGTTCAGCTGGTGCAG (SEQ ID NO: 57)

5′VH 1-24 CTGCAACCGGTGTACATTCCCAGGTCCAGCTGGTACAG (SEQ ID NO: 58)

5′VH3-33 CTGCAACCGGTGTACATTCTCAGGTGCAGCTGGTGGAG (SEQ ID NO: 59)

5′VH 3-9 CTGCAACCGGTGTACATTCTGAAGTGCAGCTGGTGGAG (SEQ ID NO: 60)

5′VH4-39 CTGCAACCGGTGTACATTCCCAGCTGCAGCTGCAGGAG (SEQ ID NO: 61)

5′VH 6-1 CTGCAACCGGTGTACATTCCCAGGTACAGCTGCAGCAG (SEQ ID NO: 62)

3′JH 1/2/4/5 TGCGAAGTCGACGCTGAGGAGACGGTGACCAG (SEQ ID NO: 63)

3′JH 3 TGCGAAGTCGACGCTGAAGAGACGGTGACCATTG (SEQ ID NO: 64)

3′JH 6 TGCGAAGTCGACGCTGAGGAGACGGTGACCGTG (SEQ ID NO: 65)

κ light chain variable region PCR primers

5′Vκ 1-5 CTGCAACCGGTGTACATTCTGACATCCAGATGACCCAGTC (SEQ ID NO: 66)

5′Vκ 1-9 TTGTGCTGCAACCGGTGTACATTCAGACATCCAGTTGACCC AGTCT (SEQ ID NO: 67)

5′Vκ 1D-43 CTGCAACCGGTGTACATTGTGCCATCCGGATGACCCAGTC (SEQ ID NO: 68)

5′Vκ 2-24 CTGCAACCGGTGTACATGGGGATATTGTGATGACCCAGAC (SEQ ID NO: 69)

5′Vκ 2-28 CTGCAACCGGTGTACATGGGGATATTGTGATGACTCAGTC (SEQ ID NO: 70)

5′Vκ 2-30 CTGCAACCGGTGTACATGGGGATGTTGTGATGACTCAGTC (SEQ ID NO: 71)

5′Vκ 3-11 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACAC AGTC (SEQ ID NO: 72)

5′Vκ 3-15 CTGCAACCGGTGTACATTCAGAAATAGTGATGACGCAGTC (SEQ ID NO: 73)

5′Vκ 3-20 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACG CAGTCT (SEQ ID NO: 74)

5′Vκ 4-1 CTGCAACCGGTGTACATTCGGACATCGTGATGACCCAGTC (SEQ ID NO: 75)

3′Jκ 1/4 GCCACCGTACGTTTGATYTCCACCTTGGTC (SEQ ID NO: 76)

3′Jκ 2 GCCACCGTACGTTTGATCTCCAGCTTGGTC (SEQ ID NO: 77)

3′Jκ 3 GCCACCGTACGTTTGATATCCACTTTGGTC (SEQ ID NO: 78)

3′Jκ 5 GCCACCGTACGTTTAATCTCCAGTCGTGTC (SEQ ID NO: 79)

(6) Use KOD-Plus-Neo (TOYOBO, KOD401) kit PCR to amplify the heavy and light chains of antibody genes, 40μL system: 3.5μL cDNA, 20nM mixed primers, 4μL buffer, 4μL 2mM dNTPs , 2.4μL MgSO ₄ , 1μL KOD.

(7) Reaction procedure: 94°C, 2min; 45 cycles: 98°C, 10s; 58°C, 30s; 68°C, 28s.

(8) Perform an agarose gel. As shown in Figure 4, it is found that the light chains of the five antibodies are about 300 bp, and the size of the heavy chain is about 400 bp.

(9) Send PCR amplification products to Jinweizhi Biotechnology Co., Ltd. for sequencing

(10) The 5 antibody variable region sequences are as follows:

1) 9g8

Heavy chain variable region:

Light chain variable region:

DIQMTQSPSSLSASVGDRVTITCRASQRFSTFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSIPYSFGQGTKLEIKR SEQ ID No: 32; or

2) 6J19

Heavy chain variable region:

Light chain variable region:

QSVLTQPPSASGTPGERVTISCSGSSSNIGRSTVSWYQQLPGTAPKLLMYSSYQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKLTVLG SEQ ID No: 34; or

3) 7N13

Heavy chain variable region:

Light chain variable region:

AIQMTQSPSSLSASVGDRVTITCRATQGIGNELGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPRTFGQGTKVEIKR SEQ ID No: 36; or

4) 8L19

Heavy chain variable region:

Light chain variable region:

DIQMTQSPSSLSASVGDRVTITCRASQSISTFLNWYQQKPGKAPNLLIYAASSLQRGVPSRFTGSGSGTDFTLTISSLQPEDFATYYCHQTYSKPWTFGRGTKVEIER SEQ ID No: 38; or

5) 6M9

Heavy chain variable region:

Light chain variable region:

Correspondingly, its CDR region sequence is as follows:

1) 9g8

HCDR1: GGSITTSSDY SEQ ID No: 1;

HCDR2: IYYSGRT SEQ ID No: 2;

HCDR3: ARRLTYYYDSSGYANWYFDL SEQ ID No: 3;

LCDR1: QRFSTF SEQ ID No: 4;

LCDR: 2: AAS SEQ ID No: 5;

LCDR3: QQSYSIPYS SEQ ID No: 6; or

2) 6J19

HCDR1: GFTFSSYS SEQ ID No: 7;

HCDR2: ISSSGTFI SEQ ID No: 8;

HCDR3: ARERFVGVLDI SEQ ID No: 9;

LCDR1: SSNIGRST SEQ ID No: 10;

LCDR: 2: SSY SEQ ID No: 11;

LCDR3: AAWDDSLNGPV SEQ ID No: 12; or

3) 7N13

HCDR1: GFTFSSYS SEQ ID No: 13;

HCDR2: ISSSSSTM SEQ ID No: 14;

HCDR3: ARGVGATGELFDY SEQ ID No: 15;

LCDR1: QGIGNE SEQ ID No: 16;

LCDR: 2: AAS SEQ ID No: 17;

LCDR3: LQDYNYPRT SEQ ID No: 18; or

4) 8L19

HCDR1: GFTFSNYS SEQ ID No: 19;

HCDR2: ISTTGTYT SEQ ID No: 20;

HCDR3: ARPYYYGSGSPDY SEQ ID No: 21;

LCDR1: QSISTF SEQ ID No: 22;

LCDR: 2: AAS SEQ ID No: 23;

LCDR3: HQTYSKPWT SEQ ID No: 24; or

5) 6M9

HCDR1: GFTFRNYD SEQ ID No: 25;

HCDR2: ISGSGIDT SEQ ID No: 26;

HCDR3: VRGLAGAFDY SEQ ID No: 27;

LCDR1: QSVTSGY SEQ ID No: 28;

LCDR: 2: GTS SEQ ID No: 29;

LCDR3: QQHRSSPMYS SEQ ID No: 30.

Finally, it is noted that the above embodiments are only used to illustrate the implementation process and characteristics of the application, rather than limiting the technical solutions of the application. Although the application has been described in detail with reference to the above embodiments, those of ordinary skill in the art should understand: This application can still be modified or equivalently replaced, and any modification or partial replacement that does not depart from the spirit and scope of this application shall be covered by the protection scope of this application.

Claims (14)

1. An isolated anti-SAR-COV-2 antibody or antigen-binding fragment thereof, which specifically binds to the surface S protein of SAR-COV-2; it has three heavy chains of any of the following groups Complementarity determining region (HCDR) and three light chain complementarity determining regions (LCDR):

   1) 9g8

   HCDR1: GGSITTSSDY SEQ ID No: 1;

   HCDR2: IYYSGRT SEQ ID No: 2;

   HCDR3: ARRLTYYYDSSGYANWYFDL SEQ ID No: 3;

   LCDR1: QRFSTF SEQ ID No: 4;

   LCDR: 2: AAS SEQ ID No: 5;

   LCDR3: QQSYSIPYS SEQ ID No: 6; or

   2) 6J19

   HCDR1: GFTFSSYS SEQ ID No: 7;

   HCDR2: ISSSGTFI SEQ ID No: 8;

   HCDR3: ARERFVGVLDI SEQ ID No: 9;

   LCDR1: SSNIGRST SEQ ID No: 10;

   LCDR: 2: SSY SEQ ID No: 11;

   LCDR3: AAWDDSLNGPV SEQ ID No: 12; or

   3) 7N13

   HCDR1: GFTFSSYS SEQ ID No: 13;

   HCDR2: ISSSSSTM SEQ ID No: 14;

   HCDR3: ARGVGATGELFDY SEQ ID No: 15;

   LCDR1: QGIGNE SEQ ID No: 16;

   LCDR: 2: AAS SEQ ID No: 17;

   LCDR3: LQDYNYPRT SEQ ID No: 18; or

   4) 8L19

   HCDR1: GFTFSNYS SEQ ID No: 19;

   HCDR2: ISTTGTYT SEQ ID No: 20;

   HCDR3: ARPYYYGSGSPDY SEQ ID No: 21;

   LCDR1: QSISTF SEQ ID No: 22;

   LCDR: 2: AAS SEQ ID No: 23;

   LCDR3: HQTYSKPWT SEQ ID No: 24; or

   5) 6M9

   HCDR1: GFTFRNYD SEQ ID No: 25;

   HCDR2: ISGSGIDT SEQ ID No: 26;

   HCDR3: VRGLAGAFDY SEQ ID No: 27;

   LCDR1: QSVTSGY SEQ ID No: 28;

   LCDR: 2: GTS SEQ ID No: 29;

   LCDR3: QQHRSSPMYS SEQ ID No: 30.
2. An isolated anti-SAR-COV-2 antibody or antigen-binding fragment thereof, which has a heavy chain variable region and a light chain variable region as shown below;

   1) 9g8

   Heavy chain variable region:

   QLQLQESGPGLVKPSETLSLTCTVSGGSITTSSDYWGWIRQPPGKGLEWIGSIYYSGRTYYNPSLKSRVTISVDTSKNDFSLKLSSVTAADTAVYYCARRLTYYYDSSGYANWYFDLWGRGTLVTVSS SEQ ID No: 31

   Light chain variable region:

   DIQMTQSPSSLSASVGDRVTITCRASQRFSTFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSIPYSFGQGTKLEIKR SEQ ID No: 32; or

   2) 6J19

   Heavy chain variable region:

   EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMKWVRQAPGKGLEWVSTISSSGTFIKYADSLQGRFTITRDNAKTAVYLQMNSLRVEDTAVYYCARERFVGVLDIWGQGTMVTVSS SEQ ID No: 33

   Light chain variable region:

   QSVLTQPPSASGTPGERVTISCSGSSSNIGRSTVSWYQQLPGTAPKLLMYSSYQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKLTVLG SEQ ID No: 34; or

   3) 7N13

   Heavy chain variable region:

   EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTMYYG DSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARGVGATGELFDYWGQGTLVTASS SEQ ID No: 35

   Light chain variable region:

   AIQMTQSPSSLSASVGDRVTITCRATQGIGNELGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPRTFGQGTKVEIKR SEQ ID No: 36; or

   4) 8L19

   Heavy chain variable region:

   EVQLVESGGGLVKPGGSLRLSCAVSGFTFSNYSMNWVRQAPGKGLEWVSSISTTGTYTHYAGSVKGRFTISRDNAKNSLFLRMNSLRAEDTAVYYCARPYYYGSGSPDYWGQGTLVTVSS SEQ ID No: 37

   Light chain variable region:

   DIQMTQSPSSLSASVGDRVTITCRASQSISTFLNWYQQKPGKAPNLLIYAASSLQRGVPSRFTGSGSGTDFTLTISSLQPEDFATYYCHQTYSKPWTFGRGTKVEIER SEQ ID No: 38; or

   5) 6M9

   Heavy chain variable region:

   EVQLLESGGGLVKPGGSLRLSCAASGFTFRNYDINWVRQAPGKGLEWVSSISGSGIDTYYGDSVEGRFTVSRDNAESSVLLEMNSLRADDTAVFYCVRGLAGAFDYWGQGTLVTVSS SEQ ID No: 39

   Light chain variable region:

   EIVLTQSPGTLSLSPGERATLSCRASQSVTSGYLAWYQQKPGQAPRLLIHGTSRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHRSSPMYSFGQGSKLEIKR SEQ ID No: 40.
3. The antibody or antigen-binding fragment thereof according to claim 1 or claim 2, wherein the antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof.
4. A nucleotide sequence characterized in that it encodes the antibody or antigen-binding fragment thereof according to any one of claims 1-3.
5. A vector, characterized in that it contains the nucleotide sequence of claim 4.
6. A host cell characterized by comprising the vector of claim 5.
7. A kit comprising the antibody or antigen-binding fragment thereof according to any one of claims 1-3.
8. A detection reagent comprising the antibody or antigen-binding fragment thereof according to any one of claims 1-3.
9. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3 as a detection reagent for the following purposes: enzyme-linked immunosorbent assay, immunoblotting, flow cytometry, immune tissue Chemical detection or immuno-PCR.
10. A pharmaceutical composition comprising the isolated antibody or antigen-binding fragment thereof according to any one of claims 1 to 3 and pharmaceutically acceptable excipients.
11. The anti-SAR-COV-2 antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, or the pharmaceutical composition according to claim 10 is at least useful in the preparation of prevention, treatment or alleviation of SAR-COV-2 infection Use in medicine for a symptom or indication;

    Preferably, the at least one symptom or indication is selected from the following group: new coronavirus pneumonia, lung inflammation, alveolar injury, fever, cough, dyspnea, hypoxemia, acute respiratory distress syndrome, sepsis Shock, coagulopathy, metabolic acidosis, nasal congestion, runny nose, sore throat, diarrhea, organ failure, septic shock and death.
12. A method for preventing, treating or alleviating at least one symptom or indication of SAR-COV-2 infection, the method comprising combining the anti-SAR-COV-2 antibody according to any one of claims 1 to 3 or its The antigen-binding fragment or the pharmaceutical composition of claim 10 is administered to a subject;

    The at least one symptom or indication is selected from the following group: new coronavirus pneumonia, lung inflammation, alveolar injury, fever, cough, dyspnea, hypoxemia, acute respiratory distress syndrome, septic shock, coagulation Dysfunction, metabolic acidosis, nasal congestion, runny nose, sore throat, diarrhea, organ failure, septic shock and death.
13. The method according to claim 12, wherein the pharmaceutical composition or the antibody or antigen-binding fragment thereof is administered in combination with a second therapeutic agent; wherein the second therapeutic agent is selected from the group consisting of anti-inflammatory drugs, antiviral drugs Drugs, different antibodies against the S protein of SAR-COV-2, vaccines for SAR-COV-2, antibiotics, dietary supplements, and other palliative therapies for the treatment of SAR-COV-2 infection, alleviating the above symptoms or indications drug.
14. The method of claim 12, wherein the pharmaceutical composition or the antibody or antigen-binding fragment thereof is administered subcutaneously, intravenously, intracutaneously, intraperitoneally, orally, intramuscularly, or intracranially.

Images